These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30521757)

  • 21. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea.
    Abad VC; Guilleminault C
    Expert Rev Respir Med; 2018 Dec; 12(12):1007-1019. PubMed ID: 30365900
    [No Abstract]   [Full Text] [Related]  

  • 24. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome.
    Black JE; Hirshkowitz M
    Sleep; 2005 Apr; 28(4):464-71. PubMed ID: 16171291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC; Sheehan AH; Jordan JK
    J Pharm Pract; 2022 Dec; 35(6):963-970. PubMed ID: 33882756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario.
    Singh H; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Thorpy MJ
    Adv Ther; 2022 Sep; 39(9):4359-4373. PubMed ID: 35927541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
    Yang J; Gao J
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):723-728. PubMed ID: 31215815
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
    Ruoff C; Swick TJ; Doekel R; Emsellem HA; Feldman NT; Rosenberg R; Bream G; Khayrallah MA; Lu Y; Black J
    Sleep; 2016 Jul; 39(7):1379-87. PubMed ID: 27166238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial.
    Pépin JL; Georgiev O; Tiholov R; Attali V; Verbraecken J; Buyse B; Partinen M; Fietze I; Belev G; Dokic D; Tamisier R; Lévy P; Lecomte I; Lecomte JM; Schwartz JC; Dauvilliers Y;
    Chest; 2021 Apr; 159(4):1598-1609. PubMed ID: 33121980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
    Pitre T; Mah J; Roberts S; Desai K; Gu Y; Ryan C; Busse JW; Zeraatkar D
    Ann Intern Med; 2023 May; 176(5):676-684. PubMed ID: 37155992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
    Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA
    J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
    Zomorodi K; Chen D; Lee L; Swearingen D; Carter LP
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):404-413. PubMed ID: 32935460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC
    Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness.
    Fuller MC; Carlson S; Pysick H; Berry V; Tondryk A; Swartz H; Cornett EM; Kaye AM; Viswanath O; Urits I; Kaye AD
    Psychopharmacol Bull; 2024 Mar; 54(1):65-86. PubMed ID: 38449471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.
    Inoue Y; Takasaki Y; Yamashiro Y
    J Clin Sleep Med; 2013 Aug; 9(8):751-7. PubMed ID: 23946704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings.
    Rosenberg R; Babson K; Menno D; Morris S; Baladi M; Hyman D; Black J
    J Sleep Res; 2022 Apr; 31(2):e13476. PubMed ID: 34545626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
    Zomorodi K; Kankam M; Lu Y
    Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions.
    Devine JK; Schwartz L; Hursh S; Asin J; de Vries N; Vonk PE; Vermeeren A; Donjacour CEHM; Vinckenbosch F; Ramaekers JG; Janssen H; Wang G; Chen D; Carter LP; Overeem S; Lammers GJ
    Neurol Ther; 2023 Feb; 12(1):249-265. PubMed ID: 36494591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Persistent Excessive Daytime Sleepiness in OSA.
    Javaheri S; Javaheri S
    Chest; 2020 Aug; 158(2):776-786. PubMed ID: 32147246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.